[Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
The results of examination of 58 patients in the course of multiple myeloma (MM) are discussed. Prognosis for LDH, beta2-m and FNO-alpha administration was evaluated versus immunochemical pattern, tumor mass and response to different chemotherapeutic regimens. High prognostic value of serum levels of LDH, beta2 and FNO-alpha in MM patients was observed. The method may be useful in carrying out chemotherapy and detecting recurrences and chemoresistance.
Abdulkadyrov
K M
KM
Russian Research Institute of Hematology and Transfusiology, Municipal Diagnostic Center, St.Petersburg.
Stel'mashenko
L V
LV
Bessmel'tsev
S S
SS
Lubo-Lesnichenko
I F
IF
Sel'tser
A V
AV
Rozanova
O E
OE
Gubarenko
N K
NK
Bubnova
L N
LN
Mnuskina
M M
MM
Zhuchikhina
A A
AA
Blinov
M N
MN
Gritskevich
N L
NL
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy / Q000276:immunology*; D011237:Predictive Value of Tests; D011379:Prognosis; D001613:beta 2-Microglobulin / Q000378:metabolism
D014408:Biomarkers, Tumor; D001613:beta 2-Microglobulin; D007770:L-Lactate Dehydrogenase